Ensifentrine clinical trials
Also written RPL554.
How each study uses ensifentrine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ensifentrine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Jun 2024 · OHTUVAYRE · NDA 217389 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Verona Pharma plc (11) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (3) · Nuance Pharma (shanghai) Co., Ltd (2) · Merck Sharp & Dohme LLC (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ensifentrine.
- Mar 2027Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)Phase 2 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Studies
Open first, then newest update. How each study uses ensifentrine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07874815Written as Ensifentrine
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)Active, not recruitingPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT05270525Written as Ensifentrine
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)CompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07016412Written as Ensifentrine 3 mg
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07132983Written as Ensifentrine 3 mg
- A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 3Nuance Pharma (shanghai) Co., LtdNCT05743075Written as Ensifentrine
- Effect of Ensifentrine Treatment on CAT ScoreCompletedPhase 3Verona Pharma plcNCT06460493Written as Ensifentrine 3 mg twice daily
- A Study of RPL554 in Patients With Cystic FibrosisCompletedPhase 2Verona Pharma plcNCT02919995Written as RPL554
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedPhase 3Verona Pharma plcNCT04535986Written as Ensifentrine
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedPhase 3Verona Pharma plcNCT04542057Written as Ensifentrine
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese SubjectsCompletedPhase 1Nuance Pharma (shanghai) Co., LtdNCT05758428Written as Ensifentrine
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Verona Pharma plcNCT04091360Written as Part A: RPL554
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDCompletedPhase 2Verona Pharma plcNCT03673670Written as RPL554 Suspension
- Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2Verona Pharma plcNCT03443414Written as RPL554 suspension
- The Effects of RPL554 in Addition to Tiotropium in COPD PatientsCompletedPhase 2Verona Pharma plcNCT03028142Written as 1.5 mg RPL554 plus tiotropium
- Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsCompletedPhase 2Verona Pharma plcNCT02427165Written as RPL554
- The Effects of RPL554 on Top of Standard COPD Reliever MedicationsCompletedPhase 2Verona Pharma plcNCT02542254Written as RPL554
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsCompletedPhase 1Verona Pharma plcNCT02307162Written as RPL554
As the comparator · 1 — what is tested is compared with ensifentrine
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call ensifentrine · ClinicalTrials.gg INT004961
- MeSH (NLM) C512996ensifentrineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3E3D8T1GIXENSIFENTRINEConfirmed FDA, NLM, Wikidata
- Wikidata Q135257708ensifentrineConfirmed FDA, NLM, Wikidata
- Wikidata Q7277486ensifentrine (stereochemically undefined)Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C166674EnsifentrineOne source FDA
- DrugBank DB16157One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C512996 | ensifentrine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3E3D8T1GIX | ENSIFENTRINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q135257708 | ensifentrine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7277486 | ensifentrine (stereochemically undefined) | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166674 | Ensifentrine | One source FDA |
| DrugBank | DB16157 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.